| Autor: |
El-Shabrawi MH; Pediatric Hepatology Department, Cairo Faculty of Medicine., Abdo AM; Tropical Medicine and Hepatology Department, Alexandria Faculty of Medicine., El-Khayat HR; Gastroenterology and Endemic Medicine Department, Theodore Research Institute, Cairo., Yakoot M; Green CRC, Alexandria, Egypt. |
| Jazyk: |
angličtina |
| Zdroj: |
Journal of pediatric gastroenterology and nutrition [J Pediatr Gastroenterol Nutr] 2018 Mar; Vol. 66 (3), pp. 425-427. |
| DOI: |
10.1097/MPG.0000000000001838 |
| Abstrakt: |
Recently, sofosbuvir and the fixed-dose combination of sofosbuvir/ledipasvir were approved for the treatment of chronic hepatitis C virus infection in adolescents, criteria being 12 years old and above or weighing at least 35 kg. Here we present the results of a pilot single cohort of 10 consecutive adolescent patients with chronic hepatitis C virus and treated with dual sofosbuvir/daclatasvir therapy for a response-tailored duration of 8 weeks for those who achieved very rapid virologic response (vRVR) and 12 weeks for those who did not. All patients achieved vRVR at week 2 and completed the shortened 8 weeks course. All patients (10/10) (100% [confidence interval 72.25-100%]) achieved sustained vRVR at week 12 post-treatment with good tolerability and no serious adverse events. These data could provide support to our suggested response-tailored protocol of dual therapy with sofosbuvir/daclatasvir in adolescents particularly for shortened duration in those who achieved vRVR. Further larger randomized controlled studies are recommended. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
Plný text